亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Sacubitril/valsartan compared to ramipril in high‐risk post‐myocardial infarction patients stratified according to use of mineralocorticoid receptor antagonists: insight from the PARADISE MI trial

医学 缬沙坦 雷米普利 内科学 危险系数 临床终点 心力衰竭 心脏病学 心肌梗塞 螺内酯 沙库比林 中止 血管紧张素转换酶抑制剂 依那普利 依瓦布拉定 置信区间 临床试验 射血分数 血压 血管紧张素转换酶 心率
作者
Morten Schou,Brian Claggett,Zi Michael Miao,Alberto Fernández,Gerasimos Filippatos,Christopher B. Granger,Karola Jering,Aldo P. Maggioni,Finnian R. Mc Causland,Julio Núñez,Jean‐Lucien Rouleau,Freny Vaghaiwalla Mody,Peter van der Meer,Dragoş Vinereanu,Martina M. McGrath,Yinong Zhou,Douglas L. Mann,Scott D. Solomon,Philippe Gabríel Steg,Eugene Braunwald,John J.V. McMurray,Marc A. Pfeffer,Lars Køber
出处
期刊:European Journal of Heart Failure [Elsevier BV]
卷期号:26 (1): 130-139 被引量:2
标识
DOI:10.1002/ejhf.3079
摘要

Abstract Aim It is unknown whether safety and clinical endpoints by use of sacubitril/valsartan (an angiotensin receptor–neprilysin inhibitor [ARNI]) are affected by mineralocorticoid receptor antagonists (MRA) in high‐risk myocardial infarction (MI) patients. The aim of this study was to examine whether MRA modifies safety and clinical endpoints by use of sacubitril/valsartan in patients with a MI and left ventricular systolic dysfunction (LVSD) and/or pulmonary congestion. Methods and results Patients ( n = 5661) included in the PARADISE MI trial (Prospective ARNI vs. ACE Inhibitor Trial to Determine Superiority in Reducing Heart Failure Events After MI) were stratified according to MRA. Primary outcomes in this substudy were worsening heart failure or cardiovascular death. Safety was defined as symptomatic hypotension, hyperkalaemia >5.5 mmol/L, or permanent drug discontinuation. A total of 2338 patients (41%) were treated with MRA. Safety of ARNI compared to ramipril was not altered significantly by ± MRA, and both groups had similar increase in symptomatic hypotension with ARNI. In patients taking MRA, the risk of hyperkalaemia or permanent drug discontinuation was not significantly altered by ARNI ( p > 0.05 for all comparisons). The effect of ARNI compared with ramipril was similar in those who were and were not taking MRA (hazard ratio [HR] MRA 0.96, 95% confidence interval [CI] 0.77–1.19 and HR MRA– 0.87, 95% CI 0.71–1.05, for the primary endpoint; p = 0.51 for interaction [Clinical Endpoint Committee adjudicated]); similar findings were observed if investigator‐reported endpoints were evaluated ( p = 0.61 for interaction). Conclusions Use of a MRA did not modify safety or clinical endpoints related to initiation of ARNI compared to ramipril in the post‐MI setting in patients with LVSD and/or congestion.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
杪夏二八完成签到 ,获得积分10
31秒前
souther完成签到,获得积分0
38秒前
乐乐应助Akitten采纳,获得10
42秒前
55秒前
kangkang发布了新的文献求助10
59秒前
传奇完成签到 ,获得积分10
1分钟前
jyy关闭了jyy文献求助
1分钟前
丘比特应助怕孤单的思雁采纳,获得10
1分钟前
2分钟前
2分钟前
Akitten发布了新的文献求助10
2分钟前
2分钟前
Li完成签到,获得积分10
2分钟前
2分钟前
自然的衫完成签到 ,获得积分10
3分钟前
3分钟前
阿巴阿巴茶完成签到,获得积分10
3分钟前
lhy发布了新的文献求助10
3分钟前
CipherSage应助科研通管家采纳,获得10
3分钟前
资白玉完成签到 ,获得积分0
4分钟前
华仔应助Akitten采纳,获得10
5分钟前
上官若男应助紫色奶萨采纳,获得10
5分钟前
老石完成签到 ,获得积分10
5分钟前
NexusExplorer应助科研通管家采纳,获得10
5分钟前
5分钟前
紫色奶萨发布了新的文献求助10
5分钟前
紫色奶萨完成签到,获得积分10
5分钟前
华仔应助怕孤单的思雁采纳,获得10
5分钟前
5分钟前
5分钟前
5分钟前
Akitten发布了新的文献求助10
6分钟前
SYLH应助怕孤单的思雁采纳,获得10
6分钟前
6分钟前
科研小白完成签到 ,获得积分10
6分钟前
6分钟前
活力半凡发布了新的文献求助10
6分钟前
6分钟前
婼汐完成签到 ,获得积分10
7分钟前
活力半凡完成签到,获得积分10
7分钟前
高分求助中
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3990298
求助须知:如何正确求助?哪些是违规求助? 3532146
关于积分的说明 11256481
捐赠科研通 3271042
什么是DOI,文献DOI怎么找? 1805197
邀请新用户注册赠送积分活动 882302
科研通“疑难数据库(出版商)”最低求助积分说明 809234